Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catheter PrecisionFRA:4RM 27 Equity-to-Asset is 0.48 as of Jun. 2026, which is 27% below its 10-year median of 0.66. GuruFocus rates FRA:4RM with a GF Score™ of 27/100 and a GF Value™ of €739.86. The stock has 9 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Catheter Precision ranks worse than 69.21% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Catheter Precision's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €15.24 Mil. Catheter Precision's Total Assets for the quarter that ended in Jun. 2026 was €32.00 Mil.
Therefore, Catheter Precision's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.48.
The historical rank and industry rank for Catheter Precision's Equity-to-Asset or its related term are showing as below:
FRA:4RM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.84 Med: 0.66 Max: 0.9
Current: 0.48
During the past 10 years, the highest Equity to Asset Ratio of Catheter Precision was 0.90. The lowest was -0.84. And the median was 0.66.
FRA:4RM's Equity-to-Asset is ranked worse than 69.21% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs FRA:4RM: 0.48
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Catheter Precision Equity-to-Asset Related Terms
Catheter Precision Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Catheter Precision's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4RM vs ODYY, BJDX, RBOT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Catheter Precision's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catheter Precision Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Catheter Precision's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Catheter Precision's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catheter Precision (FRA:4RM) has a Equity-to-Asset of 0.48 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Catheter Precision and its competitors. This is 27% below median its historical median of 0.66. According to the industry distribution chart, Catheter Precision ranks #589 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 69.2%.
Is Catheter Precision's Equity-to-Asset too high?
Catheter Precision's current Equity-to-Asset of 0.48 is 27% below median its 10-year median of 0.66. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Catheter Precision's value of 0.48 is 25% below this industry median. Based on the distribution chart, Catheter Precision ranks #589 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Catheter Precision has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Catheter Precision's Equity-to-Asset compare to ODYY and BJDX?
According to the Medical Devices & Instruments industry distribution chart, Catheter Precision ranks #589 out of 851 companies for Equity-to-Asset. This places Catheter Precision in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Catheter Precision's value of 0.48 is 25% below this benchmark. While the company's 10-year median is 0.66 vs. the industry median of 0.64, Catheter Precision has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catheter Precision's current Equity-to-Asset of 0.48 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Catheter Precision and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catheter Precision's current Equity-to-Asset is 0.48, which is 27% below median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catheter Precision stock overvalued right now?
Catheter Precision (FRA:4RM) has a current Equity-to-Asset of 0.48. The stock's GF Value™ is €739.86, compared to a current price of €100.89 — trading 86.4% below its estimated fair value. The current Equity-to-Asset is 0.48, which is 27% below median its 10-year median of 0.66 and 25% below the Medical Devices & Instruments industry median of 0.64. Catheter Precision's overall GF Score™ is 27/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Catheter Precision (FRA:4RM), the current Equity-to-Asset is 0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catheter Precision (FRA:4RM) Overvalued in 2026?
Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued.
The current stock price of €100.89 is trading 86.4% below its estimated GF Value™ of €739.86.
Key valuation signals for FRA:4RM:
Equity-to-Asset: 0.48 (27% below median its 10-year median of 0.66)
GF Value™: €739.86 vs. price of €100.89 (86.4% below fair value)
Industry Position: 25% below the Medical Devices & Instruments median (#589 of 851)
No single metric tells the full story. See the FRA:4RM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
27GF Score
Get the complete analysis for FRA:4RM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RM has been successfully added to your 
